NYSE:AMRX 23 December 2025 - 8 January 2026

Amgen shares rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.”

Amgen Inc. ended Monday, December 22, 2025, modestly higher, but the more important story for Tuesday’s open is what hit after the closing bell: fresh FDA approvals for new denosumab biosimilars that reference Amgen’s blockbuster bone-drug franchises Prolia and XGEVA—plus a credit-rating upgrade from Fitch that underscores improving balance-sheet flexibility.